Emergency Number
Prostate cancer is one of the cancers that are common across the world. As per the statistics, it is known to be the second most common cancer in the US and UK and the sixth common cause of cancer deaths in the world. As far as India is concerned, the rates earlier were quite lower compared to other countries. But, the recent data shows a rise in cancer in India and mostly in urban areas, particularly since the time.
Now, males hormones are such that they only aid in worsening the symptoms and aiding its spread. Nubeqa or darolutamide is the new drug that is effective in controlling cancer spread. It has the ability to increase the life expectancy rates by more than double.
As per the trial investigator and medical direction Neal Shore of Carolina Urologic Research Centre Prostate cancer particularly that’s spread across the other body parts is highly sensitive to the spread fast under the influence of male hormones like testosterone and testosterone metabolites.
Shore added the initial trials of the drug were a success as the tolerance was quite good events unique to ARIs that were observed in the earlier trials are not observed with darolutamide. Only that certain side effects like Nubeqa, rash and fatigue
He also added that the FDA approved the med only after it cleared the Phase III ARAMIS trial with positive results showing a rise in metastasis-free survival (MFS). Published in the New England Journal of Medicine earlier this year, had carried out the trial that involved 1509 participants who were provided with 600 mg of the oral drug two times a day or a placebo alongside ADT. The randomized trial was multicenter, double-blinded, and placebo-controlled on men with nmCRPC and under the treatment of androgen deprivation therapy (ADT) with higher chances of turning out to be metastatic.
Robert Lacaze, executive member of the pharmaceuticals division as well as strategic business head at Bayer stated that Nubeqa’s approval had opened gates to a new therapy that aids in extending MFS besides allowing physicians more flexibility in treating men having nmCRPC.
As per Matthew Smith, MD, Ph.D., director at the Massachusetts General Hospital Cancer Centre in Boston for Genitourinary malignancies program, The approval of Nubeqa has opened the gates for a new option in prostate cancer treatment. He added that the objective of the treatment was to curb the spread of cancer besides controlling therapy side effects as Patients usually do not exhibit any typical symptoms of MFS.
